Olema Pharmaceuticals (OLMA) Total Current Liabilities (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Total Current Liabilities data on file, last reported at $47.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 80.97% year-over-year to $47.2 million in Q1 2026; TTM through Mar 2026 was $47.2 million, a 80.97% increase from a year earlier, with the FY2025 full-year figure at $51.8 million, up 24.05% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $47.2 million, down from $51.8 million in the prior quarter.
• Over the last five years, Total Current Liabilities for OLMA reached as high as $51.8 million in Q4 2025 and fell as low as $117000.0 in Q1 2022.
• Historically, Total Current Liabilities has averaged $25.8 million across 5 years, with a median of $26.1 million in 2025.
• Across the five-year window, Total Current Liabilities jumped 16489.74% in 2023 and declined 0.61% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $16.5 million in 2022, then soared by 30.65% to $21.6 million in 2023, then surged by 93.14% to $41.8 million in 2024, then increased by 24.05% to $51.8 million in 2025, then dropped by 8.95% to $47.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $47.2 million in Q1 2026, $51.8 million in Q4 2025, and $41.7 million in Q3 2025.